{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:51:34Z","timestamp":1776815494656,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017104","name":"Yokohama City University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jphs.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:30:20Z","timestamp":1775604620000},"page":"32-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-0058","authenticated-orcid":false,"given":"Daiki","family":"Masukawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ichimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jphs.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.jphs.2026.04.002_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881120986422","article-title":"Hallucinogenic\/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action","volume":"35","author":"Dos Santos","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2026.04.002_bib4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3389\/fphar.2019.01119","article-title":"l-DOPA and its receptor GPR143: implications for pathogenesis and therapy in Parkinson's disease","volume":"10","author":"Goshima","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1254\/jphs.14R03CR","article-title":"Cardiovascular actions of DOPA mediated by the gene product of ocular albinism 1","volume":"126","author":"Goshima","year":"2014","journal-title":"J Pharmacol Sci"},{"issue":"1\u20133","key":"10.1016\/j.jphs.2026.04.002_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2006.08.031","article-title":"Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats","volume":"549","author":"Izawa","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jnc.15789","article-title":"Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum","volume":"165","author":"Masukawa","year":"2023","journal-title":"J Neurochem"},{"issue":"18","key":"10.1016\/j.jphs.2026.04.002_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90903","article-title":"L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor","volume":"2","author":"Masukawa","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jphs.2026.04.002_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainres.2015.01.020","article-title":"Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs","volume":"1602","author":"Fukuda","year":"2015","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.jphs.2026.04.002_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jphs.2020.07.003","article-title":"Genetic associations of single nucleotide polymorphisms in the l-DOPA receptor (GPR143) gene with severity of nicotine dependence in Japanese individuals, and attenuation of nicotine reinforcement in Gpr143 gene-deficient mice","volume":"144","author":"Masukawa","year":"2020","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.jphs.2026.04.002_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jphs.2024.07.009","article-title":"Opposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors","volume":"156","author":"Tajika","year":"2024","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.jphs.2026.04.002_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/npr2.70075","article-title":"Possible involvement of hallucinogenic effects in the aversive effects induced by Kappa-Opioid and 5-HT(2A) (\/2C) receptor agonists in mice","volume":"45","author":"Kato","year":"2025","journal-title":"Neuropsychopharmacol Rep"},{"issue":"8","key":"10.1016\/j.jphs.2026.04.002_bib13","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.jphs.2026.04.002_bib14","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1046\/j.1460-9568.1999.00858.x","article-title":"Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat","volume":"11","author":"Millan","year":"1999","journal-title":"Eur J Neurosci"},{"issue":"2\u20133","key":"10.1016\/j.jphs.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(96)00021-4","article-title":"Activation of c-fos in the brain","volume":"50","author":"Herrera","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jphs.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways","volume":"36","author":"Lopez-Gimenez","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"issue":"23","key":"10.1016\/j.jphs.2026.04.002_bib17","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1523\/JNEUROSCI.20-23-08846.2000","article-title":"DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons","volume":"20","author":"Scruggs","year":"2000","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2026.04.002_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"issue":"7","key":"10.1016\/j.jphs.2026.04.002_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1248\/bpb.b23-00217","article-title":"L-DOPA receptor GPR143 functionally couples with adrenergic alpha(1B) receptor at the second transmembrane interface","volume":"46","author":"Masukawa","year":"2023","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"10.1016\/j.jphs.2026.04.002_bib20","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1504-23.2024","article-title":"Enhancement of haloperidol-induced catalepsy by GPR143, an L-Dopa receptor, in striatal cholinergic interneurons","volume":"44","author":"Arai","year":"2024","journal-title":"J Neurosci"},{"key":"10.1016\/j.jphs.2026.04.002_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpsyt.2017.00152","article-title":"Novel psychoactive substances-recent progress on neuropharmacological mechanisms of action for selected drugs","volume":"8","author":"Hassan","year":"2017","journal-title":"Front Psychiatr"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861326000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861326000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:30:07Z","timestamp":1776814207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861326000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1347861326000186"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2026.04.002","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}